David Kendall will become MannKind Corp.'s chief medical officer Feb. 12.
Kendall, who has over three decades of experience, will replace Raymond Urbanski, who stepped down in September 2017 to pursue an opportunity elsewhere.
Kendall was most recently the vice president and research physician of Lilly Diabetes, a unit of Eli Lilly and Co.
At MannKind, he will assume full responsibility for leading scientific research, clinical development, regulatory and medical affairs activity.
Westlake Village, Calif.-based MannKind is focused on the development of treatments for diabetes and pulmonary arterial hypertension.
